Back to results
US 10,702,570 B2Granted
Compositions targeting the interaction domain between p27KiP1 and Brk and methods of use thereof to inhibit p27 Y phosphorylation and cdk4 activity
AssigneeThe Research Foundation for The State University of New York
InventorStacy W. Blain
Life of this patent
Estimating the term…
Abstract
Compositions and methods for the treatment of malignancy are disclosed.
Claims11
A pharmaceutical composition comprising an isolated Alt-Brk peptide of SEQ ID NO:
- 17 or an SH3 domain containing fragment thereof and a carrier which enhances cellular uptake and optionally a cell penetrating peptide sequence, wherein said carrier is a lipoplexed nanoparticle,
- wherein said lipoplexed nanoparticle comprises 1,2-di-O-octdecenyl-3-trimethyl ammonium propane (DOTMA), cholesterol at a molar ratio of 49.5:49.5 and a pharmaceutically acceptable carrier, and a lipid to peptide mass ratio of 20:1 or 10:1.
A pharmaceutical composition comprising an isolated Alt-Brk peptide of SEQ ID NO:
- 17 comprising 0, 1, 2, 3, or 4 mutated amino acids and truncated by 0, 1, 2, 3, or 4 amino acids, or of SEQ ID NO:
- 2 comprising 0, 1, 2, 3, or 4 mutated amino acids and truncated by 0, 1, 2, 3, or 4 amino acids, and a carrier which enhances cellular uptake and optionally a cell penetrating peptide sequence, wherein said carrier is a lipoplexed nanoparticle,
- wherein said lipoplexed nanoparticle comprises 1,2-di-O-octdecenyl-3-trimethyl ammonium propane (DOTMA), cholesterol at a molar ratio of 49.5:49.5 and a pharmaceutically acceptable carrier, and a lipid to peptide mass ratio of 20:1 or 10:1.
Dependencies are inferred from the claim text.